To study the sensitivity of the mutant cells to SOD1 inhibition, we engineered truncating PPM1D mutations into three patient-derived AML cell lines, MOLM-13, OCI-AML2, and OCI-AML3, which harbor distinct genetic backgrounds and AML driver mutations. Here, RUNX2 is linked to acute myeloid leukemia.